Clinigen Group (CLIN) Given “Buy” Rating at N+1 Singer
A number of other equities research analysts have also recently issued reports on the stock. Numis Securities reaffirmed an add rating and issued a GBX 1,208 ($16.38) price objective on shares of Clinigen Group in a research note on Wednesday. Peel Hunt reaffirmed a buy rating and issued a GBX 1,350 ($18.31) price objective on shares of Clinigen Group in a research note on Wednesday. Royal Bank of Canada reaffirmed an outperform rating and issued a GBX 1,360 ($18.44) price objective on shares of Clinigen Group in a research note on Tuesday, November 7th. Finally, Berenberg Bank assumed coverage on shares of Clinigen Group in a research note on Wednesday, November 1st. They issued a hold rating and a GBX 1,200 ($16.27) price objective for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Clinigen Group presently has an average rating of Buy and an average target price of GBX 1,222.17 ($16.57).
Clinigen Group (LON CLIN) traded up GBX 9 ($0.12) during mid-day trading on Wednesday, reaching GBX 1,059 ($14.36). 698,030 shares of the company’s stock were exchanged, compared to its average volume of 372,742. Clinigen Group has a fifty-two week low of GBX 751.50 ($10.19) and a fifty-two week high of GBX 1,187 ($16.10). The stock has a market cap of $1,300.00 and a PE ratio of 35,300.00.
COPYRIGHT VIOLATION WARNING: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/01/21/clinigen-group-clin-given-buy-rating-at-n1-singer.html.
About Clinigen Group
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.